Insta
J&J Seeks Approval For Clinical Trials Of Its Single-Shot COVID-19 Vaccine On Adolescents Aged 12-17 Years In India
Swarajya Staff
Aug 20, 2021, 01:06 PM | Updated 01:06 PM IST
Save & read from anywhere!
Bookmark stories for easy access on any device or the Swarajya app.
United States-based pharma giant Johnson and Johnson (J&J) has sought approval for clinical trial of its single-shot Covid-19 vaccine on adolescents aged 12-17 years in India.
The single-shot Covid vaccine developed by Johnson and Johnson has shown 85 per cent efficacy in preventing severe Covid-19 disease in phase 3 clinical trials.
"Johnson & Johnson is committed to facilitating global equitable access to its COVID-19 vaccine and recognize the unmet needs of children. On August 17, 2021, we submitted an application to the Central Drugs Standard Control Organisation (CDSCO) to conduct a study of the Johnson & Johnson COVID-19 vaccine in India in adolescents aged 12 – 17 years," Johnson & Johnson India spokesperson was quoted in a Economic Times report as saying.
Earlier this month, the single shot vaccine of J&J became the second COVID-19 vaccine which has been granted Emergency Use Authorisation (EUA) through the fast-track approval route by the Drug Controller General of India.
J&J has partnered with Indian vaccine maker Biological E Ltd for supply and manufacturing of its Covid-19 vaccine shot in the country.
Save & read from anywhere!
Bookmark stories for easy access on any device or the Swarajya app.
Introducing ElectionsHQ + 50 Ground Reports Project
The 2024 elections might seem easy to guess, but there are some important questions that shouldn't be missed.
Do freebies still sway voters? Do people prioritise infrastructure when voting? How will Punjab vote?
The answers to these questions provide great insights into where we, as a country, are headed in the years to come.
Swarajya is starting a project with an aim to do 50 solid ground stories and a smart commentary service on WhatsApp, a one-of-a-kind. We'd love your support during this election season.
Click below to contribute.